---
document_datetime: 2025-12-29 12:07:21
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/xerava.html
document_name: xerava.html
version: success
processing_time: 0.1084542
conversion_datetime: 2025-12-29 23:26:33.875231
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Xerava

[RSS](/en/individual-human-medicine.xml/66660)

##### Authorised

This medicine is authorised for use in the European Union

eravacycline Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Xerava](#news-on)
- [More information on Xerava](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Xerava is an antibiotic used to treat complicated intra-abdominal (belly) infections (cIAI) in adults. 'Complicated' means that the infection is difficult to treat because it has spread to the abdominal space.

Xerava contains the active substance eravacycline.

Expand section

Collapse section

## How is Xerava used?

Xerava can only be obtained with a prescription and prescribers should take into account official guidance on the use of antibiotics.

Xerava is given by infusion (drip) into a vein over one hour. The medicine is given once every 12 hours for at least 4 days and up to 14 days. The dose depends on the patient's bodyweight, and may be increased if the patient is also taking a type of medicine called a 'strong CYP3A4 inducer'.

For more information about using Xerava, see the package leaflet or contact your doctor or pharmacist.

## How does Xerava work?

The active substance in Xerava, eravacycline, belongs to a group of antibiotics called tetracyclines. Tetracyclines work by binding to and blocking part of the cell machinery in bacterial cells that is involved in making proteins. This leads to death of the bacteria causing the infection.

## What benefits of Xerava have been shown in studies?

Xerava was shown to be as effective as alternative antibiotics in 2 main studies of adults with cIAIs. The main measure of effectiveness in both studies was whether the infection was cured.

In the first study involving 538 patients, Xerava was compared with ertapenem (another antibiotic). After around a month, 87% of patients treated with Xerava were cured of their infection, compared to 89% of patients treated with ertapenem.

In the second study involving 499 patients, Xerava was compared with meropenem (another antibiotic). After around a month, 92% of patients treated with Xerava and 92% of patients treated with meropenem were cured of their infection.

## What are the risks associated with Xerava?

The most common side effects with Xerava (which may affect up to 1 in 10 people) are thrombophlebitis (inflammation of veins caused by a blood clot), phlebitis (inflammation of a vein), nausea (feeling sick), vomiting and reactions at the site of the infusion including reddening of skin, reduced sense of touch and pain. For the full list of side effects of Xerava, see the package leaflet.

Xerava must not be used in patients who are hypersensitive (allergic) to any of the ingredients of the medicine or to other tetracycline antibiotics.

## Why is Xerava authorised in the EU?

Xerava is as effective as alternative antibiotics in treating infections caused by various types of bacteria and produced high cure rates. Xerava's safety profile was considered acceptable. Therefore the European Medicines Agency decided that Xerava's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Xerava?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Xerava have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Xerava are continuously monitored. Side effects reported with Xerava are carefully evaluated and any necessary action taken to protect patients.

## Other information about Xerava

Xerava received a marketing authorisation valid throughout the EU on 20.09.2018.

Xerava : EPAR - Medicine overview

Reference Number: EMA/521584/2018

English (EN) (73.41 KB - PDF)

**First published:** 08/10/2018

[View](/en/documents/overview/xerava-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-572)

български (BG) (97.83 KB - PDF)

**First published:**

08/10/2018

[View](/bg/documents/overview/xerava-epar-medicine-overview_bg.pdf)

español (ES) (72.33 KB - PDF)

**First published:**

08/10/2018

[View](/es/documents/overview/xerava-epar-medicine-overview_es.pdf)

čeština (CS) (94.4 KB - PDF)

**First published:**

08/10/2018

[View](/cs/documents/overview/xerava-epar-medicine-overview_cs.pdf)

dansk (DA) (71.75 KB - PDF)

**First published:**

08/10/2018

[View](/da/documents/overview/xerava-epar-medicine-overview_da.pdf)

Deutsch (DE) (72.99 KB - PDF)

**First published:**

08/10/2018

[View](/de/documents/overview/xerava-epar-medicine-overview_de.pdf)

eesti keel (ET) (71.62 KB - PDF)

**First published:**

08/10/2018

[View](/et/documents/overview/xerava-epar-medicine-overview_et.pdf)

ελληνικά (EL) (104.25 KB - PDF)

**First published:**

08/10/2018

[View](/el/documents/overview/xerava-epar-medicine-overview_el.pdf)

français (FR) (73.27 KB - PDF)

**First published:**

08/10/2018

[View](/fr/documents/overview/xerava-epar-medicine-overview_fr.pdf)

hrvatski (HR) (92.24 KB - PDF)

**First published:**

08/10/2018

[View](/hr/documents/overview/xerava-epar-medicine-overview_hr.pdf)

italiano (IT) (71.66 KB - PDF)

**First published:**

08/10/2018

[View](/it/documents/overview/xerava-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (101.85 KB - PDF)

**First published:**

08/10/2018

[View](/lv/documents/overview/xerava-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (94.62 KB - PDF)

**First published:**

08/10/2018

[View](/lt/documents/overview/xerava-epar-medicine-overview_lt.pdf)

magyar (HU) (91.7 KB - PDF)

**First published:**

08/10/2018

[View](/hu/documents/overview/xerava-epar-medicine-overview_hu.pdf)

Malti (MT) (95.58 KB - PDF)

**First published:**

08/10/2018

[View](/mt/documents/overview/xerava-epar-medicine-overview_mt.pdf)

Nederlands (NL) (71.99 KB - PDF)

**First published:**

08/10/2018

[View](/nl/documents/overview/xerava-epar-medicine-overview_nl.pdf)

polski (PL) (96.12 KB - PDF)

**First published:**

08/10/2018

[View](/pl/documents/overview/xerava-epar-medicine-overview_pl.pdf)

português (PT) (72.25 KB - PDF)

**First published:**

08/10/2018

[View](/pt/documents/overview/xerava-epar-medicine-overview_pt.pdf)

română (RO) (99.7 KB - PDF)

**First published:**

08/10/2018

[View](/ro/documents/overview/xerava-epar-medicine-overview_ro.pdf)

slovenčina (SK) (95.5 KB - PDF)

**First published:**

08/10/2018

[View](/sk/documents/overview/xerava-epar-medicine-overview_sk.pdf)

slovenščina (SL) (90.64 KB - PDF)

**First published:**

08/10/2018

[View](/sl/documents/overview/xerava-epar-medicine-overview_sl.pdf)

Suomi (FI) (71.6 KB - PDF)

**First published:**

08/10/2018

[View](/fi/documents/overview/xerava-epar-medicine-overview_fi.pdf)

svenska (SV) (71.93 KB - PDF)

**First published:**

08/10/2018

[View](/sv/documents/overview/xerava-epar-medicine-overview_sv.pdf)

Xerava : EPAR - Risk-management-plan summary

English (EN) (198.19 KB - PDF)

**First published:** 08/10/2018

**Last updated:** 20/04/2023

[View](/en/documents/rmp-summary/xerava-epar-risk-management-plan-summary_en.pdf)

## Product information

Xerava : EPAR - Product Information

English (EN) (640.59 KB - PDF)

**First published:** 08/10/2018

**Last updated:** 06/11/2024

[View](/en/documents/product-information/xerava-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-531)

български (BG) (712.42 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/bg/documents/product-information/xerava-epar-product-information_bg.pdf)

español (ES) (633.29 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/es/documents/product-information/xerava-epar-product-information_es.pdf)

čeština (CS) (760.23 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/cs/documents/product-information/xerava-epar-product-information_cs.pdf)

dansk (DA) (611.42 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/da/documents/product-information/xerava-epar-product-information_da.pdf)

Deutsch (DE) (542.43 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/de/documents/product-information/xerava-epar-product-information_de.pdf)

eesti keel (ET) (599.54 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/et/documents/product-information/xerava-epar-product-information_et.pdf)

ελληνικά (EL) (725.03 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/el/documents/product-information/xerava-epar-product-information_el.pdf)

français (FR) (698.21 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/fr/documents/product-information/xerava-epar-product-information_fr.pdf)

hrvatski (HR) (635.82 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/hr/documents/product-information/xerava-epar-product-information_hr.pdf)

íslenska (IS) (603.65 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/is/documents/product-information/xerava-epar-product-information_is.pdf)

italiano (IT) (617.76 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/it/documents/product-information/xerava-epar-product-information_it.pdf)

latviešu valoda (LV) (702.33 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/lv/documents/product-information/xerava-epar-product-information_lv.pdf)

lietuvių kalba (LT) (672.26 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/lt/documents/product-information/xerava-epar-product-information_lt.pdf)

magyar (HU) (683.18 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/hu/documents/product-information/xerava-epar-product-information_hu.pdf)

Malti (MT) (840.04 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/mt/documents/product-information/xerava-epar-product-information_mt.pdf)

Nederlands (NL) (643.75 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/nl/documents/product-information/xerava-epar-product-information_nl.pdf)

norsk (NO) (590.97 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/no/documents/product-information/xerava-epar-product-information_no.pdf)

polski (PL) (694.62 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/pl/documents/product-information/xerava-epar-product-information_pl.pdf)

português (PT) (642.29 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/pt/documents/product-information/xerava-epar-product-information_pt.pdf)

română (RO) (698.96 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/ro/documents/product-information/xerava-epar-product-information_ro.pdf)

slovenčina (SK) (751.62 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/sk/documents/product-information/xerava-epar-product-information_sk.pdf)

slovenščina (SL) (663.02 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/sl/documents/product-information/xerava-epar-product-information_sl.pdf)

Suomi (FI) (621.62 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/fi/documents/product-information/xerava-epar-product-information_fi.pdf)

svenska (SV) (592.75 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

06/11/2024

[View](/sv/documents/product-information/xerava-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0028 24/10/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Xerava : EPAR - All Authorised presentations

English (EN) (57.58 KB - PDF)

**First published:** 08/10/2018

**Last updated:** 20/07/2021

[View](/en/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-904)

български (BG) (67.81 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/bg/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_bg.pdf)

español (ES) (57.81 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/es/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_es.pdf)

čeština (CS) (47.6 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/cs/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (59.75 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/da/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (60.42 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/de/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (57.63 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/et/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.37 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/el/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_el.pdf)

français (FR) (58.53 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/fr/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (114.49 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/hr/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (60.01 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/is/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_is.pdf)

italiano (IT) (57.38 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/it/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.5 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/lv/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (75.32 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/lt/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (77.14 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/hu/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (76.84 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/mt/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (58.04 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/nl/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (59.84 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/no/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_no.pdf)

polski (PL) (75.5 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/pl/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.53 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/pt/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.9 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/ro/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (74.37 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/sk/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (66.45 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/sl/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.04 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/fi/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (58.67 KB - PDF)

**First published:**

08/10/2018

**Last updated:**

20/07/2021

[View](/sv/documents/all-authorised-presentations/xerava-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Xerava Active substance eravacycline International non-proprietary name (INN) or common name eravacycline Therapeutic area (MeSH)

- Infection
- Bacterial Infections

Anatomical therapeutic chemical (ATC) code J01AA

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/004237 Marketing authorisation holder

PAION Pharma GmbH

Heussstraße 25 Brand 52078 Aachen Germany

Marketing authorisation issued 20/09/2018 Revision 9

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Xerava : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (180.62 KB - PDF)

**First published:** 10/07/2019

**Last updated:** 06/11/2024

[View](/en/documents/procedural-steps-after/xerava-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Xerava : EPAR - Public assessment report

Reference Number: EMA/540193/2018

English (EN) (2.99 MB - PDF)

**First published:** 08/10/2018

[View](/en/documents/assessment-report/xerava-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Xerava

Adopted

Reference Number: EMA/CHMP/447907/2018

English (EN) (68.46 KB - PDF)

**First published:** 27/07/2018

**Last updated:** 27/07/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-xerava_en.pdf)

#### News on Xerava

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-july-2018) 27/07/2018

#### More information on Xerava

- [EMEA-001555-PIP01-13-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001555-pip01-13-m05)
- [Xerava - opinion on variation to marketing authorisation](/en/medicines/human/variation/xerava)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/11/2024

## Share this page

[Back to top](#main-content)